You should see the attachment in the forwarded email. If not update code to fix it

June 27, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

I appreciate you sharing your medical context, but I'm not seeing:

  1. Your actual pathology report — The text, image, or PDF you'd like me to summarize
  2. Your patient profile details — While you've mentioned follicular lymphoma and asked about liquid biopsy innovations, I don't have your specific diagnosis details (stage, prior treatments, biomarkers, etc.)
  3. The attachment — You mentioned "You should see the attachment in the forwarded email" but no file came through

TL;DR

I can't summarize your pathology without seeing it—please share the actual report, and I'll explain what it means in plain language.

KEY POINTS

  • Pathology reports contain critical information about your lymphoma type, grade, and biomarkers
  • I need the actual document to give you an accurate, personalized summary
  • Once you share it, I can explain how it relates to liquid biopsy testing options
  • Your specific findings will determine which innovations are most relevant for you
  • Understanding your pathology helps you have better conversations with your oncology team

NEXT STEP

Please paste or upload your pathology report in your next message, and I'll provide a complete plain-language summary tailored to your follicular lymphoma.


FULL ANSWER

I'm ready to help you understand your pathology report and discuss liquid biopsy innovations for follicular lymphoma, but I need the actual document.

What to share:

  • Copy-paste the pathology report text directly into the chat
  • Upload an image or PDF of your report
  • Include any lab results or biomarker testing (like LDH, Ki-67, genetic mutations)
  • Share your stage and any prior treatments if relevant

What I'll provide once you share:

  1. Plain-language summary of what your pathology shows
  2. Explanation of key findings — what each result means for FL specifically
  3. Biomarker interpretation — how your specific findings guide treatment
  4. Liquid biopsy relevance — which innovations (like ctDNA/MRD testing) apply to YOUR case
  5. Questions to ask your oncologist — based on your specific pathology findings

Why this matters: Your pathology report is the foundation for all treatment decisions. Understanding it helps you:

  • Know your exact diagnosis and prognosis
  • Understand which treatments are most likely to work for your specific lymphoma
  • Decide whether liquid biopsy monitoring makes sense for you
  • Ask informed questions about clinical trials or new testing options

According to the NCCN Guidelines for B-Cell Lymphomas, pathology findings determine:

  • Whether you have follicular lymphoma (vs. other lymphomas)
  • Your grade (1-3a, which affects prognosis and treatment intensity)
  • Biomarkers like BCL2/BCL6 translocations (which may guide targeted therapy)
  • Whether you're a candidate for newer approaches like MRD testing with ctDNA

Once you share your report, I can:

  • Explain what each section means
  • Connect your findings to the liquid biopsy innovations you asked about
  • Help you understand how your specific pathology influences whether tests like the Foresight CLARITY Lymphoma test would be useful for you
  • Prepare you for conversations with your oncology team

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2

It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated

Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter